ALK and adenocarcinoma: Compared with the non‐ALK&ROS1/EGFR cases in NSCLC patients, the ALK&ROS1‐positive group that significantly differed from the non‐ALK&ROS1/EGFR group was younger (χ2 = 19.920, P < 0.001); the majority were female (χ2 = 28.152, P < 0.001), non‐smoking (χ2 = 11.080, P = 0.001), and adenocarcinoma (χ2 = 12.318, P = 0.002) patients; proportion of patients with lymphangitis was higher (χ2 = 4.647, P = 0.046); and proportion of patients with emphysema was lower (χ2 = 15.770, P < 0.001) (Table 2).